A. De Ponti

NMS-E973, a Novel Synthetic Inhibitor of Hsp90 with Activity against Multiple Models of Drug Resistance to Targeted Agents, Including Intracranial Metastases

A. Isacchi, E. Casale, E. Felder, 2013, Clinical Cancer Research.

Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.

P. Cappella, F. Sola, R. Alzani, 2010, Anticancer research.

Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.

D. Ballinari, V. Croci, D. Volpi, 2010, Journal of medicinal chemistry.

NMS-P937, an Orally Available, Specific Small-Molecule Polo-like Kinase 1 Inhibitor with Antitumor Activity in Solid and Hematologic Malignancies

A. Isacchi, E. Felder, D. Ballinari, 2012, Molecular Cancer Therapeutics.